Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, Jeffrey A. Gelfand
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to immune treatment of a disease (e.g., an infectious disease) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.
Claims27
A method for treating a pathogen-related disease in a patient wherein said pathogen induces or expresses chemorepellant properties, the method comprising:
- a) administering to the patient an effective amount of a fusion protein which fusion protein comprises a pathogen binding component and a stress protein component, wherein said pathogen binding component binds to the pathogen, pathogen-associated antigen, or a pathogen-infected cell and said stress protein component activates antigen-presenting cells;
- and
- b) concurrently administering to said patient an effective amount of an anti-chemorepellant agent;
- wherein the combination of the fusion protein and the anti-chemorepellant agent treat the pathogen-related disease.
(canceled)
8-16. (canceled)
A pharmaceutical composition comprising a fusion protein and an anti-chemorepellant agent, said fusion protein comprising a pathogen binding component and a stress protein component.
26-31. (canceled)
A kit of parts for treatment of a pathogen-related disease in a patient, the kit comprising a therapeutically effective amount of an anti-chemorepellant agent and a fusion protein comprising a pathogen binding component and a stress protein component, wherein the pathogen binding component recognizes an antigen expressed by the pathogen or a cell infected by the pathogen.
39-41. (canceled)
Dependencies are inferred from the claim text.